University of Dundee - Confidence in Concept 2014

Lead Research Organisation: University of Dundee
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The University of Dundee and its Drug Discovery Unit (DDU) is converting world-class discovery research into patient benefit through a portfolio of small molecule translational projects, the Innovative Targets Portfolio (ITP). The ITP, initiated by an MRC-DPFS devolved portfolio and extended with the first two Confidence in Concept awards, is a collaborative activity between the DDU and groups in and outside Dundee who wish to translate their discovery research.
The primary goal of the ITP is to de-risk novel targets and mechanisms to the stage that the BioPharma industry is willing to partner the project for development into marketed therapies to address unmet medical need. The ITP is a dynamic initiative, with projects entering and leaving the portfolio in a continuous rolling process.
Although the ITP is supported by a range of funding streams, these funds are insufficient to meet the demand from multiple potential collaborators, both within Dundee and across the UK, who have identified novel potential drug targets and are seeking to translate their ideas.
A renewed Confidence in Concept award would help maintain the resources available to run multiple hit discovery campaigns and hit series validation projects by the DDU. The aim is to determine the druggability/ligandability of novel targets/mechanisms and to identify high quality hit series, validated in cell-based models. The requested resources will synergise with the ITP team members supported through other funding routes, providing excellent added-value to the Confidence in Concept award.
We believe a portfolio approach is the best way to maximise resource in early stage drug discovery. This approach allows multiple projects to rapidly access an appropriate amount of hit discovery and medicinal chemistry, in a cost-effective way, to assess whether they justify further drug discovery efforts and progression towards in vivo evaluation. This will be achieved using appropriate funding streams e.g. MRC-DPFS/DCS scheme.
The University of Dundee already has the infrastructure and experience required to continue to deliver success under expanded further Confidence in Concept award, including: assay development, hit discovery, medicinal and computational chemistry, and pharmacokinetics.
 
Description European Lead Factory
Amount £500,000 (GBP)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Public
Country Belgium
Start 05/2017 
 
Description High growth spinout
Amount £131,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 08/2020 
End 03/2021
 
Description MRC
Amount £823,000 (GBP)
Funding ID MR/P000509/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description project grant
Amount £209,048 (GBP)
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2014 
End 12/2016
 
Description project grant
Amount £261,067 (GBP)
Organisation Arch Therapeutics 
Sector Private
Country United States
Start 01/2017 
End 12/2019
 
Description translational medical research fund 2014
Amount £18,500 (GBP)
Organisation University of Dundee 
Sector Academic/University
Country United Kingdom
Start 03/2014 
 
Description Hit TB TbCoABC sub-project 
Organisation Foundation for the National Institutes of Health (FNIH)
Country United States 
Sector Charity/Non Profit 
PI Contribution Data and assays generated by the CiC supported HTS project. The hit Tb grant (our funded resource from the collaboration) we will support 1 FTE years chemistry and computational chemistry plus purchasing of commercial analogues of the hits.
Collaborator Contribution Structural biology Tb cell biology and animal model work on selected examples. Fragment screening data and assays.
Impact To early to generate defined outputs
Start Year 2015
 
Description Investment Partnership Agreement 
Organisation Perceptive Bioscience Holdings Ltd
Country United Kingdom 
Sector Academic/University 
PI Contribution The University has signed an Investment Partnership Agreement with Perceptive that will allow the DDU to further translate programmes developed with MRC CiC funding up to preclinical candidates.
Collaborator Contribution Perceptive will underwrite the CURE Fund for up to 10 years.
Impact The investment sum will be disclosed later in the year.
Start Year 2016
 
Company Name HepaRegeniX GmbH 
Description HepaRegeniX is a biopharmaceutical company focused on the discovery, development and clinical testing of selective and potent MKK4 inhibitors for liver disease and human tissue regeneration. The company, spun out of the University of Tubingen, was registered in January 2016 and has signed a collaboration with the DDU in Dundee where we have developed an screening assay for MKK4 and completed a diversity screen. The group in Germany was introduced to us through Boehringer Ingelheim Venture Fund who were looking for Dundee input to the technology before they committed to funding a spinout. 
Year Established 2016 
Impact Heparegenix currently only has a handfull of employees but is expected to have 20 by the year end when full funding has been secured. Dundee will be awarded £154,000 to acquire sole ownership of the Dundee MKK4 data.
Website http://www.recently-registered.com/www/heparegenix.com
 
Company Name HepaRegeniX GmbH 
Description HepaRegeniX is a biopharmaceutical company focused on the discovery, development and clinical testing of selective and potent MKK4 inhibitors for liver disease and human tissue regeneration. The company, spun out of the University of Tubingen, was registered in January 2016 and has signed a collaboration with the DDU in Dundee where we have developed an screening assay for MKK4 and completed a diversity screen. The group in Germany was introduced to us through Boehringer Ingelheim Venture Fund who were looking for Dundee input to the technology before they committed to funding a spinout. 
Year Established 2016 
Impact Heparegenix currently only has a handfull of employees but is expected to have 20 by the year end when full funding has been secured. Dundee will be awarded £154,000 to acquire sole ownership of the Dundee MKK4 data.
Website http://www.recently-registered.com/www/heparegenix.com